Actionable insights straight to your inbox

Equities logo

Amgen Reports 6% Rise in Q2 Revenue, in Line With Estimates; Beats Profit Forecasts

Higher sales of newer drugs, like recently-added psoriasis treatment Otezla, offset declining sales of older medicines. Adjusted earnings rose 4% to $2.52 billion, or $4.25 per share, vs estimates of $3.84.
The company, with a market cap of $1.22 billion and revenue of just $6 million, had four candidate drugs in clinical trials, including one that was named a China National Priority project.